查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495995

全球皮肤病治疗市场：2024-2029 年预测

Global Dermatological Drug Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 125 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计在预测期内，皮肤科治疗市场将以 9.10% 的复合年增长率成长，从 2022 年的 299.31 亿美元增至 2029 年的 550.76 亿美元。

皮肤科是治疗皮肤、头髮和指甲疾病的医学领域，其中最常见的是干癣、湿疹和寻常性痤疮。皮肤科药物用于治疗和控制皮肤、指甲、头髮和生殖膜疾病。近年来，由于全球营养缺乏、不良饮食习惯、压力增加、污染和免疫力减弱，患有皮肤病的人数迅速增加。

因此，对治疗皮肤病的适当治疗方法和皮肤病药物的需求正在增加。市场区隔是按适应症、给药途径、最终用户和地区分類的。

市场驱动因素

  • 皮肤病患病率的增加和医疗保健领域研发的活性化预计将导致市场快速扩张。

推动皮肤病治疗产业的最重要因素之一是皮肤病患病率的上升。创伤、环境因素、遗传因素和老龄化只是导致全世界数百万人患有皮肤病的主要变数中的一些。自2013年以来，世界各地都庆祝世界皮肤健康日，以提高人们的认识并治疗各种皮肤病。据世界卫生组织 (WHO) 称，皮肤病是最常见的健康疾病之一，在任何特定时间都会影响全球近 9 亿人。

随着老龄化，人类皮肤开始失去健康功能，导致各种皮肤病的发生，皮肤科药物市场正在不断发展。此外，随着年龄的增长，我们开始遇到各种其他问题，包括伤口癒合缓慢、对紫外线 (UV) 辐射的敏感性增加、对感染疾病的敏感性增加以及皮下脂肪减少。根据澳洲的一项研究，寻常性痤疮长期影响超过 4% 的人口。因此，由于皮肤病发生频率的增加和对有效药物的需求增加，预计市场在预测期内将以更快的速度发展。

据美国皮肤病学会称，痤疮是最常见的皮肤病，每年影响美国4000 至 5000 万人。这种情况在年轻人中更为常见，12 岁至 24 岁之间的人中有 85% 患有某种形式的痤疮。据美国红斑痤疮协会称，酒糟患者数量正在增加，仅在美国就有 1600 万人患有这种疾病。全球皮肤科药品市场可能会受到定期推出新颖且以客户为中心的产品的进一步影响。例如，Sol-Gel Technologies 于 2021 年 7 月宣布 TWYNEO 获得 FDA 批准。这是一种外用乳膏，用于治疗成人和 9 岁以上儿童的寻常痤疮。

市场限制：

  • 由于产品使用不当而产生不良反应的风险可能成为皮肤病治疗市场的限制因素。

新兴国家因不良饮食习惯、污染以及吸烟、饮酒等不健康的生活习惯而遭受皮肤感染疾病的人口占世界人口的很大一部分。在低收入和中等收入国家，由于缺乏有关皮肤问题的资讯和高文盲率，皮肤科治疗的普及正在下降。与产品相关的不利影响也是阻碍市场成长的问题。例如，美国食品药物管理局(FDA) 已发布关于使用某些可能引起危及生命的过敏反应的非处方药的建议。预计这将减少产品的采用并降低皮肤病治疗的市场价值。

预计北美将在全球市场中占据主要份额。

由于皮肤病治疗药物易于取得，预计在预测期内北美将占据皮肤病治疗市场的很大一部分。此外，皮肤炎、痤疮、干癣等皮肤病发病率的增加也是推动该市场成长的一个突出因素。同时，人们对皮肤病治疗方法的认识不断提高也推动了该市场的成长。

随着技术的进步，有关皮肤科药物使用的常识也有所增加。此外，透过提高人们的美学敏感性，他们正在帮助扩大皮肤科治疗的市场。

主要进展

  • 2023 年 12 月 - Arcutis Biotherapeutics 宣布罗氟司特霜 (ZORYVE) 0.3% 外用泡沫，一种外用磷酸二酯酶 4 抑製剂，用于治疗 12 岁及以上人群的斑块状斑块型干癣和9 岁及以上族群的脂漏性皮肤炎获得FDA核准。 Zorive Foam 是一种每日一次、不含类固醇、安全、有效且耐受性良好的泡沫，可用于所有受影响的区域，包括头髮。
  • 2023 年 1 月 - 百时美施贵宝 (Bristol-Myers Squibb) 的口服药物 Sotyktu 用于治疗中度至重度斑块型干癣成人患者获得了 CHMP 的积极评价。 Sotyktu 是一种选择性 TYK2 抑制剂，与安慰剂和 Otezla 相比，在皮肤清除、症状负担和生活品质方面表现出显着改善。欧盟委员会审查的建议该药物耐受性良好，因不利事件而停药的比率较低。 FDA 于 2022 年 9 月核准了Sotyktu，在日本，厚生劳动省核准将其用于对传统治疗没有充分反应的斑块型干癣、全身脓疱型干癣和红皮病型干癣成人患者。
  • 2022年1月－美国食品药物管理局（FDA）核准RINVOQ®（通用名： Upadacitinib ）用于治疗成人及12岁以上儿童的中度至重度异位性皮肤炎。此次核准是基于一项涉及 2,500 多名患者的 3 期项目的有效性和安全性资料。在同一项研究中，与安慰剂相比，搔痒早在第 1 週就显着改善，早在第 16 週就观察到皮肤清除情况。在美国，RINVOQ 15mg 和 30mg 被核准用于患有难治性中度至重度异位性皮肤炎的成人和儿童患者。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球皮肤病治疗市场：依适应症分类

  • 介绍
  • 干癣
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 粉刺
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 皮肤炎
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章皮肤病治疗的全球市场：途径分类

  • 介绍
  • 外用
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 口服
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 胃肠外的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章全球皮肤病治疗市场：依最终用户分类

  • 介绍
  • 医院和诊所
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 化妆品中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球皮肤科治疗市场：按地区

  • 介绍
  • 北美洲
    • 按指示
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按指示
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按指示
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按指示
    • 依给药途径
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按指示
    • 依给药途径
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • AbbVie Inc
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Leo Pharma A/S
  • Merck KGaA
  • Nestle SA
  • Novartis AG
  • Pfizer Inc
  • Curatio Healthcare
简介目录
Product Code: KSI061612156

The global dermatological drug market is projected to grow at a CAGR of 9.10% during the forecast period to reach US$55.076 billion by 2029, up from US$29.931 billion in 2022.

Dermatology is a field of medicine that deals with diseases of the skin, hair, and nails, with psoriasis, eczema, and acne vulgaris being the most common. Dermatology medications are used to treat and manage diseases of the skin, nails, hair, and genital membranes. Due to reasons such as nutritional inadequacy, bad eating habits, increased stress, pollution, and a lack of immunity in the worldwide population, the pool of people affected by dermatological problems has rapidly expanded in recent years.

The demand for appropriate treatment methods and dermatological medications for the treatment of dermatological disorders has risen as a result. The global dermatological drug market is segmented by indication, route of administration, end-user, and geography.

Market Drivers:

  • The increasing prevalence of dermatological conditions and the rise in research and development in healthcare are anticipated to surge the market.

One of the most important factors driving the dermatological medication industry is the rising prevalence of skin diseases. Trauma, environmental and hereditary factors, and age are only a few of the major variables that contribute to the development of skin diseases in millions of people around the world. Since 2013, World Skin Health Day has been observed around the world to raise awareness of and treat a variety of skin conditions. According to the World Health Organization (WHO), skin diseases are one of the most common types of health disorders, affecting nearly 900 million people worldwide at any given time.

The healthy functioning of the human skin begins to deteriorate with age, leading to an incidence of various skin diseases, propelling the dermatology drug market forward. Furthermore, as people get older, they begin to experience a variety of other issues, including slower wound healing, increased sensitivity to ultraviolet (UV) radiation, increased susceptibility to infections, and a loss of subcutaneous fat. According to Australian research, acne vulgaris affects more than 4% of the population in the long run. As a result, the market is expected to develop at a faster rate during the projected period due to an increase in the frequency of skin diseases and the demand for effective medications.

Acne is the most common skin disorder, according to the American Academy of Dermatology, impacting 40 to 50 million people in the United States each year. It is more common in younger people, with 85% of people aged 12 to 24 suffering from some kind of acne. According to the National Rosacea Society, the rosacea patient population is rising, with 16 million people in the United States alone suffering from the condition. The worldwide dermatological pharmaceutical market is likely to be impacted further by the regular release of novel and customer-centric products. For example, Sol-Gel Technologies announced FDA clearance of TWYNEO in July 2021. It's a topical cream for the treatment of acne vulgaris in adults and children aged 9 and above.

Market Restraint:

  • Risks of negative effects from incorrect product use can act as a limitation on the market for dermatological drugs.

Emerging countries account for a large share of the global population with dermatological infections owing to poor diet, pollution, and unhealthy habits such as smoking and drinking. Lack of information on skin problems, as well as a higher illiteracy rate, have resulted in decreased adoption of dermatological treatments in low-middle-income nations. The negative effects connected with the products are another issue impeding the market's growth. For example, the US Food and Drug Administration (FDA) has issued an advisory regarding the use of certain over-the-counter drugs that might induce life-threatening allergic reactions. This is anticipated to reduce product adoption, resulting in a drop in the market value of dermatology medications.

North America is expected to hold a significant share of the global market.

Due to the simple availability of dermatological drugs, North America is estimated to account for a large proportion of the dermatological drug market over the forecast period. Furthermore, an increase in the occurrence of skin ailments such as dermatitis, acne, and psoriasis is a prominent factor driving this market's rise. On the other hand, due to increased awareness about the usage of dermatological medications,

As technology advances, there is a rise in public knowledge about the usage of dermatological medications. Furthermore, it helps with the expansion of the dermatological medication market by increasing people's aesthetic sensibility.

Key Developments:

  • December 2023- Arcutis Biotherapeutics received FDA approval for its roflumilast cream (ZORYVE) 0.3% topical foam, a topical phosphodiesterase-4 inhibitor, for plaque psoriasis in patients aged 12 and above and seborrheic dermatitis in individuals aged 9 and older. ZORYVE foam is a safe, effective, and well-tolerated once-daily steroid-free foam for use on all affected areas, including hair-bearing areas. It provides rapid disease clearance and a significant reduction in itch, a common symptom of seborrheic dermatitis.
  • January 2023- Bristol Myers Squibb received a positive CHMP opinion for Sotyktu, an oral medication for adults with moderate-to-severe plaque psoriasis. Sotyktu, a selective TYK2 inhibitor, showed significant improvements in skin clearance, symptom burden, and quality of life compared to placebo and Otezla. The recommendation reviewed by the European Commission. The drug was well tolerated, with a low rate of discontinuation due to adverse events. The FDA approved Sotyktu in September 2022, while Japan's Ministry of Health, Labour and Welfare approved it for adults with plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis who have had inadequate response to conventional therapies.
  • January 2022- The U.S. Food and Drug Administration (FDA) approved RINVOQ(R) (upadacitinib) for treating moderate to severe atopic dermatitis in adults and children aged 12 years and older. The approval is based on efficacy and safety data from a Phase 3 program involving over 2,500 patients. The study showed significant improvement in itch as early as week one and skin clearance at 16 weeks compared to the placebo. In the U.S., RINVOQ 15 mg and 30 mg are approved for use in adults and pediatric patients with refractory, moderate to severe atopic dermatitis.

Key Market Segments:

By Indication

  • Psoriasis
  • Acne
  • Dermatitis
  • Others

By Route Of Administration

  • Topical
  • Oral
  • Parenteral

By End-User

  • Hospitals And Clinics
  • Cosmetic Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • Thailand
  • Indonesia
  • South Korea
  • India
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL DERMATOLOGICAL DRUG MARKET BY INDICATION

  • 5.1. Introduction
  • 5.2. Psoriasis
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Acne
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Dermatitis
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL DERMATOLOGICAL DRUG MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Topical
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Oral
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Parenteral
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL DERMATOLOGICAL DRUG MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals And Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Cosmetic Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Others
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL DERMATOLOGICAL DRUG MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Indication
    • 8.2.2. By Route of Administration
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Indication
    • 8.3.2. By Route of Administration
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Indication
    • 8.4.2. By Route of Administration
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. United Kingdom
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Indication
    • 8.5.2. By Route of Administration
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. South Africa
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Indication
    • 8.6.2. By Route of Administration
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. Japan
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Thailand
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Indonesia
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. South Korea
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. India
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Taiwan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. AbbVie Inc
  • 10.2. Amgen Inc
  • 10.3. GlaxoSmithKline Plc
  • 10.4. Johnson & Johnson
  • 10.5. Leo Pharma A/S
  • 10.6. Merck KGaA
  • 10.7. Nestle S.A
  • 10.8. Novartis AG
  • 10.9. Pfizer Inc
  • 10.10. Curatio Healthcare